Business Context and Reporting Period
This Form 6-K filing by Universe Pharmaceuticals INC (Nasdaq: UPC) covers the month of October 2024. The report discloses a change in the Company's independent registered public accounting firm, effective October 8, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of corporate governance changes rather than a financial performance report.
Material Changes
- Change of Auditor: The Company appointed Enrome LLP as its new independent registered public accounting firm, replacing YCM CPA INC.
- Reason for Change: The decision was made after careful consideration and evaluation by the Company and approved by the audit committee. It was not the result of any disagreement regarding accounting principles, financial statement disclosure, or auditing scope.
- Prior Audit Status: YCM's audit reports for the fiscal years ended September 30, 2022, and 2023, did not contain adverse opinions, disclaimers, or qualifications.
- Reportable Events: No disagreements or reportable events occurred during the two most recent fiscal years, except for material weaknesses in internal controls previously reported by management in the Form 20-F for the fiscal year ended September 30, 2023.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary on future operations. The primary risk disclosed relates to the previously identified material weaknesses in internal controls over financial reporting, which were noted in the prior annual report.
Investor Verification Checklist
- Verify the transition timeline and initial audit scope between Universe Pharmaceuticals and the new auditor, Enrome LLP.
- Review the specific details of the material weaknesses in internal controls reported in the Form 20-F for the fiscal year ended September 30, 2023.
- Confirm the content of the letter from the former auditor, YCM CPA INC, filed as Exhibit 99.1, to ensure no undisclosed disagreements exist.
- Monitor upcoming filings for the first financial statements audited by Enrome LLP.